Safety and Dose Study of Peramivir for Influenza Treatment

NCT00297050 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

NIH

Sponsor class

Conditions

Influenza

Interventions

DRUG: Peramivir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)